Profile data is unavailable for this security.
About the company
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
- Revenue in USD (TTM)107.27m
- Net income in USD6.65m
- Incorporated1997
- Employees574.00
- LocationGyre Therapeutics Inc12770 High Bluff Drive, Suite 150SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 567-7770
- Fax+1 (302) 636-5454
- Websitehttps://www.gyretx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MiMedx Group Inc | 418.63m | 48.58m | 725.00m | 808.00 | 14.67 | 2.75 | 11.14 | 1.69 | 0.3244 | 0.3244 | 2.80 | 1.73 | 1.38 | 2.97 | 6.37 | 518,106.40 | 16.02 | 11.26 | 19.56 | 14.27 | 82.56 | 82.71 | 11.60 | 7.91 | 3.92 | -- | 0.0655 | 0.00 | 19.99 | 11.02 | 15.67 | -- | -25.68 | -- |
| Kura Oncology Inc | 104.03m | -216.88m | 755.31m | 192.00 | -- | 3.05 | -- | 7.11 | -2.48 | -2.48 | 1.19 | 2.79 | 0.1844 | -- | -- | 541,817.70 | -38.45 | -26.38 | -44.88 | -28.06 | -- | -- | -208.48 | -1,266.72 | -- | -- | 0.0384 | -- | -- | -- | -13.99 | -- | -- | -- |
| Agomab Therapeutics NV | 0.00 | -66.05m | 781.60m | 62.00 | -- | -- | -- | -- | -1.36 | -1.36 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.60 | 0.009 | -- | -- | -- | -306.21 | -- | -- | -- |
| Gyre Therapeutics Inc | 107.27m | 6.65m | 796.20m | 574.00 | 122.39 | 7.05 | 50.92 | 6.69 | 0.0646 | 0.0646 | 1.09 | 1.12 | 0.7537 | 0.6368 | 4.73 | 186,872.80 | 8.30 | -53.99 | 12.90 | -82.36 | 95.48 | 89.58 | 11.01 | -88.61 | 5.64 | -- | 0.00 | -- | -6.78 | -- | 113.00 | -- | 117.68 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -237.32m | 796.78m | 166.00 | -- | 17.75 | -- | -- | -2.68 | -2.68 | 0.00 | 0.3916 | 0.00 | -- | -- | 0.00 | -94.37 | -45.17 | -169.95 | -49.01 | -- | -- | -- | -- | -- | -2.19 | 0.4541 | -- | -- | -- | -30.94 | -- | -- | -- |
| Annexon Inc | 0.00 | -208.88m | 797.89m | 99.00 | -- | 3.87 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 798.57m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Eikon Therapeutics Inc | -100.00bn | -100.00bn | 803.29m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.7508 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 806.29m | -- | 48.80 | 1.21 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| Evommune Inc | 3.00m | -66.26m | 807.33m | 45.00 | -- | -- | -- | 250.93 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 811.77m | 270.00 | -- | 46.41 | -- | 52.19 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
| Janux Therapeutics Inc | 10.00m | -113.63m | 816.36m | 109.00 | -- | 0.8482 | -- | 81.76 | -1.83 | -1.83 | 0.1614 | 15.85 | 0.0097 | -- | -- | 91,743.12 | -11.02 | -12.49 | -11.25 | -12.85 | -- | -- | -1,136.25 | -822.69 | -- | -- | 0.00 | -- | -5.55 | -- | -64.69 | -- | -- | -- |
| Prime Medicine Inc | 4.63m | -201.14m | 841.18m | 146.00 | -- | 6.32 | -- | 164.84 | -1.38 | -1.38 | 0.031 | 0.6696 | 0.0145 | -- | -- | 31,726.03 | -62.83 | -65.25 | -71.22 | -77.08 | -- | -- | -4,342.44 | -11,586.93 | -- | -- | 0.00 | -- | 55.28 | -2.32 | -2.69 | -- | 47.96 | -- |
| Omeros Corp | 0.00 | -121.24m | 849.39m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| Arvinas Inc | 262.60m | -80.80m | 856.44m | 246.00 | -- | 1.96 | -- | 3.25 | -1.22 | -1.22 | 3.70 | 6.83 | 0.2903 | -- | 78.39 | 1,067,480.00 | -8.93 | -18.57 | -11.25 | -22.95 | -- | -- | -30.77 | -141.50 | -- | -- | 0.0009 | -- | -0.3037 | 64.50 | 59.38 | -- | -21.68 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 859.92m | 15.00 | -- | 14.56 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Gyre Therapeutics Inc's reporting currency: US Dollar USD
3.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.05m | 1.16% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 675.83k | 0.74% |
| Geode Capital Management LLCas of 31 Dec 2025 | 423.22k | 0.47% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 202.23k | 0.22% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2025 | 169.16k | 0.19% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 162.92k | 0.18% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 138.08k | 0.15% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 128.86k | 0.14% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 53.97k | 0.06% |
| State of Wisconsin Investment Boardas of 31 Dec 2025 | 24.80k | 0.03% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
